 Hello Slush. Thank you for having me. I'm Samu Lehtunen, CEO and co-founder of Marginal Limited, a medical device company, developing the next generation tool in cancer surgery. We are developing a patent-pending smart tissue monitor, which enables more efficient eye-reocation tumor tissues, increasing the value, safety and efficiency of surgery. We are pursuing market entry exceptionally fast in 2024 as there is an urgent need for a solution that allows precise detection of tumor cells with minimal damage to health tissues and that can be integrated into and simplify the current surgical workflow. Our multidisciplinary team of medical doctors and technologists has the necessary expertise to successfully commercialize our invention and is passionate about its work. We are privileged to work together with global key opinion leaders in the field of surgical technology and are advised by distinguished business leaders to attain a dominant market position. Marginal was founded in 2020 and has since then won several academic and business awards for its technological breakthroughs. During brain tumor surgery, fluorescence is used to identify cancer tissue and to remove it. Prior to the operation, the patient is given a fluorescent drug, which accumulates to the cancer tissue prior to the surgery and utilizing blue fluorescence and blue emission light, the tumor tissue closed red, as is in the picture on the right. Utilizing this red fluorescence, the surgeon can identify the tumor and remove it. However, current surgical workflows are complex, resulting in suboptimal treatment for the patients and visual obstructions, such as blood and debris, often hinder the surgeon's ability to identify the tumor. Furthermore, the visibility is impaired to the contrast being utilized in the operation. However, our solution offers objective feedback and improved decision making enabling the surgeon to perform better. Unlike other monitoring systems, our solution allows to identify the tumor objectively based on 360 degree black box design, for which we have an animation to better illustrate it. Here is a simplified version of our prototype, named as an example proto, that still betrayed my name of the device still under works. Here you can see surgical suction system, which is used during the operation and used to remove tissue. Here the resected tissues, which are removed during the operation, flow through the suction tube. Usually they flow into the waste container, but in this case fluorescence emission is able to be detected with our novel method. Utilizing the same fluorescence emission identification, our device utilizing high performance detectors can identify the cancer tissue from resected residues. Based on the light intensity of the removed particles, the information can be relayed back to the surgeon, essentially enabling the surgeon to better identify the tumor and removing more of it. With this technique and without solution, surgery can be more effective, more informed and safer. We are setting new standards to the contemporary technical limitations faced daily by practicing surgeons, leading to the following three issues, undetected tumor cells, resected healthy tissues and complex operative workflows. With our solution we can utilize and identify the fluorescent intensity of the removed tissue and relay this back to the surgeon, enabling the surgeon to perform better. Without technique more of the tumor can be removed, leading to lesser healthcare cost, decreased tumor recurrence and ultimately the best possible treatment for patients. Our solution is incredibly versatile method for cancer surgery, enabling continuous monitoring and more and better treatments with the aim of removing the whole tumor in one try. Our product is highly sensitive, easily manufacturable and easily validated as opposed to contemporary visual based imaging systems and it can also operate beyond the performance of contemporary solutions. We stand out to our cost effectiveness and ease of use and our device is designed so that it can be seamlessly integrated into contemporary surgical workflows, essentially giving our collaborators a unique competitive advantage. An important distinction is that we don't see our competitors as competitors but rather as potential partners because our device and our technique can be utilized in parallel with their technique in order to produce the best possible results for the patient. Our business model utilizes licensing and subscription comprises of device sales, product upgrade and replacement service and calibration and maintenance. Our overarching vision is for our device to be compatible with one million medical devices including aspirators, catheters, robotic surgery platforms and a wide array of fluorescent probes. With this versatility and the modular design that our product uses enables us to target a wide range of medical indications. Currently there are over 70 different fluorescent inducing drugs under FDA removal to which our technology can be applied. We estimate an annual total patient count of 2.7 million with the market size being 2 billion euros. As mentioned, our MVP's first application is medical climatumus but we aim to scale our solution to cover liver cancer, ovarian cancer and gastrointestinal cancer among others. Next, we are aiming to acquire our CE marking, initiate our device's FDA approval and conduct a successful market entry. We have recently closed, our seed funding round are now essentially preparing for serious A financing. We are addressing a global problem and providing value-adding and safer treatment to surgical outcomes. Monitoring of fluorescent biomarkers in oncological surgery will be a breakthrough. We wish that during this event, if you have any questions don't hesitate to reach out to me and join us on this oncological surgical revolution. Thank you.